A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s)

AIDS Research and Human Retroviruses

Volumn 26, Issue 11, 2010, Pages 1215-1219

  Ruane, Peter ^a   Alas, Brian ^a   Ryan, Robert ^b   Perniciaro, Amy ^b   Witek, James ^b  

^a Light Source Medical   (United States)

^b Tibotec Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; CHOLESTEROL; DARUNAVIR PLUS RITONAVIR; ENFUVIRTIDE; ETRAVIRINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VIRUS RNA;

ACUTE CHOLECYSTITIS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INJECTION SITE REACTION; INSOMNIA; MALE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RASH; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS INHIBITION; WEIGHT REDUCTION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PILOT PROJECTS; PYRIDAZINES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78649239633     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0285     Document Type: Article

References (14)

1. Duffalo ML and James CW: Enfuvirtide: A novel agent for the treatment of HIV-1 infection. Ann Pharmacother 2003;37:1448-1456.
2. Nelson M, Arasteh K, Clotet B, et al.: Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005;40:404-412.
3. Reynes J, Arasteh K, Clotet B, et al.: TORO: Ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDs 2007;21:533-543.
4. FUZEON® (enfuvirtide): Full prescribing information. Available from http://www.rocheusa.com/products/fuzeon/pi.pdf. Accessed July 27th, 2009.
5. PREZISTA® (darunavir) Tablets: Full prescribing information. Available from: http://www.prezista.com/prezista/documents/us-package-insert. pdf. Accessed July 15, 2009.
6. INTELENCE® (etravirine) Tablets: Full prescribing information. Available from: http://www.intelence-info.com/intelence/assets/pdf/INTELENCE-PI. pdf. Accessed September 17, 2009.
7. Katlama C, Haubrich R, Lalezari J, et al.: Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: Pooled 48 week analysis of two randomized, controlled trials. AIDS 2009;23:2289-2300.
8. Clotet B, Bellos N, Molina JM, et al.: Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-1178.
9. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006;14:125-130.
10. Haubrich RH, Riddler SA, DiRienzo AG, et al.: Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23:1109-1118.
11. Haubrich R, Cahn P, Grinsztejn B, et al.: DUET-1: Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 612 treatment-experienced HIV-1-infected patients. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; 2008; Boston. Available from: http://www. retroconference.org/2008/PDFs/790.pdf. Accessed June 9, 2009.
12. Lazzarin A, Campbell T, Clotet B, et al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2:24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:39-48.
13. Madruga JV, Cahn P, Grinsztejn B, et al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1:24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29-38.
14. Grant PM, Palmer S, Bendavid E, et al.: Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life. J Clin Virol 2009;46:305-308.